Clinical trial
Rebif New Formulation (RNF) in Relapsing Forms of Multiple Sclerosis
NCT00110396 · EMD Serono, Industry · Completed
Key facts
| NCT number | NCT00110396 |
|---|---|
| Title | Rebif New Formulation (RNF) in Relapsing Forms of Multiple Sclerosis |
| Official title | A Multicentre, Single Arm, Open-Label, Phase IIIB Study to Evaluate the Safety and Antigenicity of Rebif® (Interferon-beta-1a) in Subjects With Relapsing Forms of Multiple Sclerosis |
| Acronym | RNF |
| Lead sponsor | EMD Serono, Industry |
| Collaborators | Pfizer Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Multiple Sclerosis |
| Intervention type | Biological |
| Interventions | Interferon-beta-1a FBS-free/HSA-free |
| Enrollment | 260 |
| Start date | Jan 1, 2005 |
| Primary completion | Apr 1, 2007 |
| Completion | Apr 1, 2007 |
| First posted | May 9, 2005 |
| Last update posted | Jul 15, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: